Semaglutide Reconstitution Calculator & Guide

Yes. Semaglutide is the active ingredient in several FDA-approved prescription products, including Ozempic, Wegovy, and Rybelsus. The approved indication depends on the specific product and patient population.

Both contain Semaglutide, but they are distinct prescription products with different FDA-approved indications, formulations, labeling, and treatment contexts. Ozempic is primarily used in adults with type 2 diabetes and has cardiovascular and kidney-related indications, while Wegovy is used for chronic weight management and has additional cardiovascular and MASH indications in specific populations.

Rybelsus and Ozempic both contain Semaglutide, but Rybelsus is an oral prescription product and Ozempic is an injectable prescription product. They have different formulations and should not be treated as interchangeable products.

Yes. Reduced hunger, increased satiety, and lower energy intake are well-described effects of Semaglutide and contribute to weight reduction in many patients.

In the STEP 1 trial, adults with obesity or overweight without diabetes assigned to Semaglutide plus lifestyle intervention lost an average of 14.9% of starting body weight at 68 weeks, compared with 2.4% with placebo plus lifestyle intervention. Results vary substantially between individuals and studies.

In the head-to-head SURMOUNT-5 trial in adults with obesity without type 2 diabetes, Tirzepatide produced greater average weight reduction than Semaglutide at 72 weeks. This does not mean every person will respond better to Tirzepatide.

Semaglutide primarily activates GLP-1 receptors. Retatrutide activates GLP-1, GIP, and glucagon receptors and remains investigational as of 2026.

Yes, for specific approved populations. In SELECT, Semaglutide reduced the relative risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 20% in adults with established cardiovascular disease and overweight or obesity without diabetes. Wegovy has an FDA-approved cardiovascular risk-reduction indication for qualifying adults.

Semaglutide has demonstrated kidney benefit in people with type 2 diabetes and chronic kidney disease. Ozempic labeling includes an indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in this population.

Wegovy received accelerated FDA approval in August 2025 for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis. Ongoing confirmatory study follow-up is intended to verify longer-term clinical benefit.

Common adverse effects are primarily gastrointestinal and include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and related digestive symptoms. The exact frequency varies by product, treatment context, and study population.

Acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists, including Semaglutide, and is included in FDA-approved prescribing information as an important warning and precaution.

Semaglutide products carry a boxed warning because thyroid C-cell tumors occurred in rodents. It is unknown whether Semaglutide causes these tumors in humans. FDA-approved labeling includes contraindications involving a personal or family history of medullary thyroid carcinoma or MEN 2.

No automatic equivalence should be assumed. FDA-approved Ozempic and Wegovy are regulated pharmaceutical products, while compounded or research products can differ in formulation, concentration, manufacturing controls, sterility, quality, and regulatory status.

Divide the labeled amount in the vial by the liquid volume. For example, 5mg divided by 2mL equals 2.5mg per mL. This is mathematical concentration conversion rather than a recommendation for how Semaglutide should be prepared.

Yes. Enter a labeled vial amount and liquid volume to calculate concentration, equivalent liquid volume, U-100 syringe units, and approximate amounts per vial. BACToBasics provides educational math rather than medical or dosing advice.